Copay Support

Otsuka, the maker of JYNARQUE® (tolvaptan), is committed to helping people with ADPKD

Copay support

Eligible patients pay no more than $10 a month for JYNARQUE*

Since JYNARQUE will be delivered directly to your door by a REMS-certified specialty pharmacy, you will not need a copay card. Tell your specialty pharmacy you are interested in lowering your out-of-pocket costs and the copay support can be applied directly.

Lab support program

Lab support program

You will need to get regular lab testing done while taking JYNARQUE. Otsuka collaborates with the 2 largest nationwide lab companies to help make sure patients taking JYNARQUE can get their monthly lab tests for free.

Contact Otsuka Patient Support Program

1-833-569-7277

Don’t have health insurance or need help affording your JYNARQUE tablets?

Call 1-855-727-6274 or click the link below to learn more about your options.

*Assumes one 28-day supply prescription per month. If more than one prescription is filled in a calendar month, you may pay more than $10 in that month. Offer is not transferable. Patients are not eligible if they are under 18 years of age, or are covered in whole or in part by any state program or federal healthcare program, including, but not limited to, Medicare or Medicaid (including Medicaid managed care), Medigap, VA, DOD, or TRICARE. Only valid in US and Puerto Rico. Offer void where prohibited by law, taxed, or restricted. Other restrictions may apply. This program is not health insurance. Otsuka America Pharmaceutical, Inc. has the right to rescind, revoke, or amend this program at any time without notice. Your participation in this program confirms that this offer is consistent with your insurance coverage and that you will report the value received if required by your insurance provider. When you use this program, you are certifying that you understand and will comply with the program rules, terms, and conditions.

COVID-19 UPDATE

With the COVID-19 situation constantly developing, your health is our top priority. We hope that you and your families are staying safe and healthy during this unprecedented time.

If you are currently taking JYNARQUE® (tolvaptan), we encourage you to stay in close contact with your healthcare professional team regarding regular appointments and treatment management plans.

At this time, there is no expected impact on medication supply.

If you have lost a job or health insurance coverage due to the COVID-19 pandemic, we have extended our patient support program to provide "no-cost" access for patients in the U.S. taking JYNARQUE. Please call Otsuka Patient Support at 1-855-242-7787 for more information.

For help accessing JYNARQUE, go to www.otsukapatientsupport.com/jynarque or call Otsuka Patient Support at 1-855-242-7787. The nurses at Otsuka Patient Support can answer questions related to Product Accessibility, Reimbursement and connecting patients to local treatment sites in their community.

Please read FULL PRESCRIBING INFORMATION, including BOXED WARNING, and MEDICATION GUIDE.

April 202010US20EBC0044

COVID-19 UPDATE

With the COVID-19 situation constantly developing, your health is our top priority. We hope that you and your families are staying safe and healthy during this unprecedented time.

If you are currently taking JYNARQUE® (tolvaptan), we encourage you to stay in close contact with your healthcare professional team regarding regular appointments and treatment management plans.

At this time, there is no expected impact on medication supply.

If you have lost a job or health insurance coverage due to the COVID-19 pandemic, we have extended our patient support program to provide "no-cost" access for patients in the U.S. taking JYNARQUE. Please call Otsuka Patient Support at 1-855-242-7787 for more information.

For help accessing JYNARQUE, go to www.otsukapatientsupport.com/jynarque or call Otsuka Patient Support at 1-855-242-7787. The nurses at Otsuka Patient Support can answer questions related to Product Accessibility, Reimbursement and connecting patients to local treatment sites in their community.

Please read FULL PRESCRIBING INFORMATION, including BOXED WARNING, and MEDICATION GUIDE.

April 202010US20EBC0044